Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Spinal injury patients may keep stronger bones with simple infusion

NCT ID NCT02325414

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single dose of zoledronic acid, a drug already used for osteoporosis, can prevent the rapid bone loss that often follows a spinal cord injury. Researchers enrolled 60 adults who had recently lost the ability to walk due to injury. They measured changes in bone density and strength over time to see if the treatment helped preserve bone health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

60 people

The number who actually took part.

Started

Feb 2015

Finished

Aug 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * In-patient at Rehabilitation Institute of Chicago (RIC) or an outpatient who was recently discharged from RIC * Males and females * Age \>/=18 years * Medically stable in the opinion of subject's physiatrist * SCI at within 120 days inclusive at time of screening * SCI with inability to ambulate independently * ASIA Impairment Scale (AIS) A, B, or C, at time of study entry * Capable of positioning to have DXA performed * Able to tolerate acetaminophen * No known endocrinopathies (diabetes type 1 or 2 can be included) * Normal TSH levels * Normal 25-OH vitamin D levels (\>/= 20 ng/ml) at baseline (subjects may be repleted) * Normal calcium levels * Normal renal function (creatinine \<2.0 mg/dl) * Well hydrated with adequate intake of liquids * Able to return for all follow-up visits * Capable of reading and understanding informed consent document * Males and females of childbearing potential must be willing and able to use double barrier method of contraception for 2 months after having received study drug Exclusion Criteria: * Have Paget's disease of the bone * Malignancy as a cause of acute SCI * Have unexplained high levels of alkaline phosphatase in blood * Any active gastrointestinal condition that results in malabsorption * Poor dental hygiene or requirement for invasive dental procedure within two months prior to enrollment * History of bone metastasis and skeletal malignancies * History of alcoholism or drug abuse within the 2 years prior to study screening * Other medical conditions that in the opinion of the investigator would preclude the subject from completing the study * Elevated liver function tests \>2x normal * Currently being prescribed anti-convulsants at a dose or frequency that is determined to interfere with bone metabolism as determined by the investigator * Currently being prescribed glucocorticoids, other than inhaled glucocorticoids * Current or recent use any bone-active agents, including any bisphosphonate, raloxifene, hormone therapy (estrogen and estrogen/progestin), calcitonin or strontium-containing compounds within 60 days of screening. * Pregnant, planning to become pregnant, or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute spinal cord injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois, 60611, United States

  • Rehabilitation Institute of Chicago

    Chicago, Illinois, 60611, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.